Brief: Verve Establishes Global Collaboration With Lilly

Verve Therapeutics

15/06/2023 11:51

June 15 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE ESTABLISHES GLOBAL COLLABORATION WITH LILLY TO
ADVANCE
VERVE’S IN VIVO GENE EDITING PROGRAM TARGETING LP(A) FOR THE
TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    * VERVE THERAPEUTICS INC: TO RECEIVE $60 MILLION IN COMBINED
UPFRONT PAYMENT AND EQUITY INVESTMENT
    * VERVE THERAPEUTICS INC: ADDITIONAL CAPITAL POSITIONED TO
EXTEND
VERVE'S EXPECTED CASH RUNWAY INTO 2026
    * VERVE THERAPEUTICS INC: VERVE HAS OPT-IN RIGHTS TO CO-FUND
AND
SHARE IN POTENTIAL MARGINS OF PRODUCTS RESULTING FROM
COLLABORATION
    * VERVE THERAPEUTICS INC: LILLY WILL BE RESPONSIBLE FOR
SUBSEQUENT
DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION OF LP(A)
PROGRAM
    * VERVE THERAPEUTICS INC: RESEARCH PROGRAM COSTS THROUGH
PHASE 1
CLINICAL TRIALS WILL BE FUNDED BY LILLY
    * VERVE THERAPEUTICS: ALSO ELIGIBLE TO GET UP TO $465
MILLION IN
RESEARCH, DEVELOPMENT, & COMMERCIAL MILESTONES, PLUS TIERED
ROYALTIES ON GLOBAL NET SALES

Source text for Eikon:  ID:nGNXWz3tK 
Further company coverage:  VERV.O